Active	Status	Sponsor type	Region	Phase	Filter
9 Active 27 Inactive 36 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

7 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Davies, Melanie J
STRIVE, NCT03036800: Saxenda in Obesity Services ( Study)	Completed	4	392	Europe	Saxenda, Liraglutide 3mg, Specialist Obesity Management Services	University of Leicester, Novo Nordisk A/S	Obesity, Weight Loss, Diabetes Mellitus	02/21	02/22
SURPASS-EARLY, NCT05433584: A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes	Active, not recruiting	4	780	Europe, Canada, US, RoW	Tirzepatide, LY3298176, Antihyperglycemic medication	Eli Lilly and Company	Type 2 Diabetes	10/25	11/27
TRIUMPH-4, NCT05931367: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee	Active, not recruiting	3	405	Europe, Canada, US, RoW	Retatrutide, LY3437943, Placebo	Eli Lilly and Company	Obesity, Overweight, Osteo Arthritis Knee	12/25	12/25
TRIUMPH-1, NCT05929066: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight	Active, not recruiting	3	2300	Europe, Canada, US, RoW	Retatrutide, LY3437943, Placebo	Eli Lilly and Company	Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea	04/26	05/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity	Active, not recruiting	3	15374	Europe, Canada, Japan, US, RoW	Tirzepatide, LY3298176, Placebo	Eli Lilly and Company	Obesity, Overweight	10/27	10/27
VISTA, NCT06553599: Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity	Not yet recruiting	2	285	Europe, Canada, US, RoW	AZD5004, Active IMP, Placebo	AstraZeneca	Obesity or Overweight	08/25	12/25
VISTA, NCT06579092: Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity	Recruiting	2	304	Europe, Canada, Japan, US, RoW	AZD5004, Active IMP, Placebo	AstraZeneca	Obesity or Overweight	12/25	12/25